Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 22;11(15):4259.
doi: 10.3390/jcm11154259.

Association between Anti-Hepatitis C Viral Intervention Therapy and Risk of Sjögren's Syndrome: A National Retrospective Analysis

Chien-Hsueh Tung  1   2 , Yen-Chun Chen  2   3 , Yi-Chun Chen  2   4
Affiliations

Association between Anti-Hepatitis C Viral Intervention Therapy and Risk of Sjögren's Syndrome: A National Retrospective Analysis

Chien-Hsueh Tung et al. J Clin Med. .

Abstract

Hepatitis C virus (HCV) infection is a potential risk factor for Sjögren's syndrome (SS). However, it is unclear whether anti-HCV intervention therapy could decrease SS risk. A retrospective cohort analysis from 1997-2012 comprising 17,166 eligible HCV-infected adults was conducted. By 1:2 propensity score matching, a total of 2123 treated patients and 4246 untreated patients were subjected to analysis. The incidence rates and risks of SS and death were evaluated through to the end of 2012. In a total follow-up of 36,906 person-years, 177 (2.8%) patients developed SS, and 522 (8.2%) died during the study period. The incidence rates of SS for the treated and untreated cohorts were 5.3 vs. 4.7/1000 person-years, and those of death for the treated and untreated cohorts were 10.0 vs. 14.8/1000 person-years. A lower risk of death (adjusted hazard ratio, 0.68; 95% CI, 0.53-0.87) was present in HCV-infected patients receiving anti-HCV therapy in multivariable Cox regression, and this remained consistent in multivariable stratified analysis. However, there were no relationships between anti-HCV therapy and its therapeutic duration, and SS risk in multivariable Cox regression. In conclusion, anti-HCV intervention therapy was not associated with lower SS risk in HCV-infected patients, but associated with lower death risk.

Keywords: HCV infection; Sjögren’s syndrome; anti-HCV therapy; death.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of the enrollment process.
Figure 2
Figure 2
Multivariate stratified analyses for the association between anti-HCV therapy and study outcomes. Each factor was adjusted for all other factors listed in Supplementary Table S2. SS, Sjögren’s syndrome; aHR, adjusted hazard ratio; CI, confidence interval.
See this image and copyright information in PMC

References

    1. Fox R.I. Sjögren’s syndrome. Lancet. 2005;366:321–331. doi: 10.1016/S0140-6736(05)66990-5. - DOI - PubMed
    1. Shiboski S.C., Shiboski C.H., Criswell L., Baer A., Challacombe S., Lanfranchi H., Schiødt M., Umehara H., Vivino F., Zhao Y., et al. American College of Rheumatology classification criteria for Sjögren’s syndrome: A data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012;64:475–487. doi: 10.1002/acr.21591. - DOI - PMC - PubMed
    1. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., Daniels T.E., Fox P.C., Fox R.I., Kassan S.S., et al. Classification criteria for Sjögren’s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 2002;61:554–558. doi: 10.1136/ard.61.6.554. - DOI - PMC - PubMed
    1. Ramos-Casals M., Muñoz S., Zerón P.B. Hepatitis C virus and Sjögren’s syndrome: Trigger or mimic? Rheum. Dis. Clin. North Am. 2008;34:869–884. doi: 10.1016/j.rdc.2008.08.007. - DOI - PubMed
    1. Pastore F., Martocchia A., Stefanelli M., Prunas P., Giordano S., Toussan L., Devito A., Falaschi P. Hepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environment. World J. Hepatol. 2016;8:83–91. doi: 10.4254/wjh.v8.i2.83. - DOI - PMC - PubMed

LinkOut - more resources